

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Pembrolizumab with enfortumab vedotin for untreated locally advanced or metastatic urothelial cancer [ID6332]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company Astellas (enfortumab vedotin) Patient/carer groups Action Bladder Cancer UK Black Health Agency for Equality Bladder and Bowel Community Bladder and Bowel UK Cancer Black Care Cancer Equality Cancer 52 Fight Bladder Cancer Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Pelican Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Healthcare professional groups Association of Cancer Physicians British Association of Urological Nurses British Association of Urological Surgeons British Geriatrics Society British Griatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee Possible comparator companies Advanz Pharma (methotrexate) Amgen (filgrastim, pegfilgrastim) Baxter (doxorubicin) Cipla (methotrexate) Hospira UK (carboplatin, cisplatin, gemcitabine, methotrexate, vinblastine) Medac GmbH (doxorubicin, methotrexate) Morningside Healthcare (methotrexate) Napp Pharmaceuticals (pegfilgrastim)
British Society of Urogenital Radiology	

Provisional stakeholder list for the evaluation of Pembrolizumab with enfortumab vedotin for untreated locally advanced or metastatic urothelial cancer ID6332 Issue date: August 2024



Consultees	Commentators (no right to submit or appeal)
 British Society of Urogynaecology British Uro-Oncology Group Cancer Research UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Urology Foundation Others Department of Health and Social Care NHS England 	 Pfizer (methotrexate, doxorubicin, filgrastim) Roche (atezolizumab) Rosemont Pharmaceuticals (methotrexate) Sandoz (cisplatin, pegfilgrastim, filgrastim) Seacross Pharmaceuticals (doxorubicin) Sun Pharmaceutical (gemcitabine) Synchrony Pharma (gemcitabine) Therakind (methotrexate) Teva Pharma (lipegfilgrastim) Other relevant companies: Merck Sharp and Dohme (pembrolizumab) Relevant research groups Cochrane UK Cochrane Urology Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of Pembrolizumab with enfortumab vedotin for untreated locally advanced or metastatic urothelial cancer ID6332 Issue date: August 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts, and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.